<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mechanisms of antibiotic resistance in enterococci</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mechanisms of antibiotic resistance in enterococci</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mechanisms of antibiotic resistance in enterococci</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cesar A Arias, MD, MSc, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara E Murray, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William R Miller, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Enterococci, formerly called group D streptococci, come well equipped with a variety of intrinsic (ie, naturally occurring) antibiotic resistances; they are also capable of acquiring new resistance genes and/or mutations. The combination of high-level resistance to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, and aminoglycosides continues to be common among hospital-acquired <em>Enterococcus faecium</em> in the United States and has a major impact on therapeutic options. (See  <a class="medical medical_review" href="/z/d/html/4045.html" rel="external">"Vancomycin-resistant enterococci: Epidemiology, prevention, and control"</a>.)</p><p>Problems in the treatment of enterococcal infections were noticed as early as the 1950s with the observation that enterococcal endocarditis was not cured nearly as often as streptococcal endocarditis with penicillin [<a href="#rid1">1</a>]. The reason for the poorer response appears to be that penicillin is not as bactericidal against enterococci as it is (or was in the 1950s) against most viridans-group streptococci. This phenomenon, which has been commonly described as tolerance, is characteristic of many enterococcal strains and, even in those that do not initially display tolerance, tolerance can be rapidly elicited by pulsed (intermittent) penicillin exposure. The latter observation led to some support for the use of continuous-infusion penicillin or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> in an attempt to avoid eliciting tolerance [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2"><span class="h1">GENETICS OF RESISTANCE IN ENTEROCOCCI</span><span class="headingEndMark"> — </span>Until the last few decades, enterococci could be treated with penicillin, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> with or without an aminoglycoside. Some enterococci have now acquired resistance to these and many other agents as a result of mutations (eg, causing high-level resistance to <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> or to fluoroquinolones) or the acquisition of new gene(s).</p><p>With respect to the acquisition of new genes, enterococci have several different ways of transferring DNA by conjugation (bacterial mating):</p><p class="bulletIndent1"><span class="glyph">●</span>One mechanism, involving pheromone-responsive plasmids, causes plasmid transfer between <em>Enterococcus faecalis</em> isolates at a very high frequency [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another mechanism involves other plasmids that can transfer among a broad range of species and genera, although usually at a moderately low frequency [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third mechanism (conjugative transposition) involves transfer of specialized transposons at low frequency but to a very broad range of different kinds of bacteria [<a href="#rid5">5</a>]. Conjugative transposons are relatively nonselective in their host range and are one of the few types of elements known to have crossed the gram-positive/gram-negative barrier in naturally occurring clinical isolates and to then cause resistance in these various hosts [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A fourth mechanism involves the transfer of large fragments of chromosomal DNA directly from one cell to the other via conjugation. This has been described with conjugative transposons and, in <em>E. faecalis,</em> with pheromone-responsive plasmids; with the latter, the transfer of chromosomal DNA appears to be dependent upon recombination occurring between homologous sequences present on these plasmids and the chromosome [<a href="#rid7">7</a>].</p><p></p><p>Many of the acquired resistances of enterococci involve antibiotics infrequently used to treat enterococcal infections. These include tetracyclines, macrolides, and high levels of <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and fluoroquinolones. It seems likely that these resistances have emerged among enterococci that were colonizing humans or animals to whom antibiotics were given for other reasons.</p><p>This observation serves as a reminder that the colonizing flora is at least as likely to be influenced by the use of antibiotics as is the infecting organism. Colonizing bacteria may actually be more capable of developing resistance because they coexist with multiple other bacterial species in nonsterile sites like the gastrointestinal tract and therefore have access to their resistance genes.</p><p class="headingAnchor" id="H3"><span class="h1">BETA-LACTAM RESISTANCE</span><span class="headingEndMark"> — </span>Unlike many streptococci, an important intrinsic property of enterococci is their resistance to many beta-lactam compounds. The greatest degree of resistance is to <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, which lacks activity against all gram-positive cocci, and the cephalosporins (although new generation cephalosporins, such as <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">ceftobiprole</a> and <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>, exhibit some activity against <em>E. faecalis</em> but not most <em>E. faecium</em>), followed by the antistaphylococcal penicillins such as methicillin and the carboxypenicillins such as ticarcillin.</p><p>Even with the more active beta-lactams (eg, penicillin, <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>), it takes 10 to 1000 times more drug to inhibit an average <em>Enterococcus</em> than an average <em>Streptococcus</em>. <em>E. faecalis</em>, the more susceptible of the two predominant enterococcal species, is usually inhibited by 1 to 4 mcg/mL of ampicillin and 2 to 8 mcg/mL of penicillin; the comparable minimal inhibitory concentrations (MICs) for <em>E. faecium</em> are typically 8 to 32 mcg/mL. However, <em>E. faecium</em> strains that are much more highly resistant (MICs &gt;32 mcg/mL) to ampicillin have emerged in the past several decades.</p><p class="headingAnchor" id="H4"><span class="h2">Ampicillin resistance</span><span class="headingEndMark"> — </span>A gene coding for penicillinase was first reported in staphylococci and later found, although very rarely, in enterococci [<a href="#rid8">8</a>]. Most penicillinase-producing enterococci have been <em>E. faecalis</em>, but eight isolates of <em>E. faecium</em> from a polyclonal outbreak in Italy were reported to possess the beta-lactamase gene [<a href="#rid9">9</a>].</p><p>Relatively little penicillinase is produced by enterococci in comparison with most <em>Staphylococcus aureus</em>, which can result in a problem of detection for the clinical laboratory. At the standard inoculum used for susceptibility testing, penicillinase-producing enterococci appear no more resistant to penicillin or <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> than a nonpenicillinase-producing organism; however, these organisms will show resistance at a high inoculum when more enzyme is present (<a class="graphic graphic_table graphicRef57470" href="/z/d/graphic/57470.html" rel="external">table 1</a>).</p><p>An in vivo effect of penicillinase has been demonstrated in animal models with a better response to penicillins in the presence of beta-lactamase inhibitors. The Clinical Laboratory Standards Institute (CLSI) currently recommends that, because of the rarity of penicillinase-positive enterococci, a test for penicillinase need not be performed routinely but can be used in selected cases, such as endocarditis and other serious infections [<a href="#rid10">10</a>]. If recognized, these organisms pose no real therapeutic dilemma since they are susceptible to beta-lactamase inhibitor combinations, such as <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> or <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, and to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>.</p><p>A more difficult problem is posed by enterococci with high-level resistance to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> due to a nonpenicillinase mechanism, since this resistance is not overcome by adding a beta-lactamase inhibitor. This phenotype is primarily seen in <em>E. faecium</em>. Isolates of this species recovered prior to the mid- to late 1980s, although more resistant to ampicillin than <em>E. faecalis</em>, were usually inhibited by &lt;8 to 32 mcg/mL of ampicillin. More recently, a trend toward much higher levels of resistance has been observed among nosocomial isolates, with some strains failing to be inhibited by 256 mcg/mL of ampicillin or more [<a href="#rid11">11</a>].</p><p>The intrinsic resistance of <em>E. faecium</em> appears to be due to the presence of a cell wall synthesis enzyme (encoded by a gene that is part of the core genome) that is relatively resistant to inhibition by penicillin. This low-affinity penicillin-binding protein (PBP) is called PBP5 [<a href="#rid12">12,13</a>]. There are two versions of PBP5: PBP5-R and PBP5-S. PBP5-R is typically observed in strains of hospital-associated <em>E. faecium</em> with high MICs for <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>. PBP5-S is typically found in nonclinical or community-associated strains and confers lower MICs of ampicillin. Higher levels of resistance to beta-lactam antibiotics appear to involve one or more of the following mechanisms: increased expression of PBP5-R, alterations in the PBP5 protein around the active site, and/or utilization of a beta-lactam–insensitive transpeptidase for cell wall synthesis [<a href="#rid14">14-16</a>].</p><p>Some strains of <em>E. faecalis </em>have been reported with higher than usual MICs of penicillin and/or <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>; this has been associated with amino acid changes in PBP4, the low-affinity PBP of this species. These strains may still test susceptible to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> (albeit with higher than usual MICs) and raise caution about using ampicillin susceptibility to predict susceptibility of <em>E. faecalis </em>to penicillin and carbapenems [<a href="#rid17">17-19</a>]. A similar discrepancy has been noted between ampicillin and <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>, with some suggesting that ampicillin susceptibility may also not imply piperacillin susceptibility (particularly when <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> is used as an antienterococcal agent in intra-abdominal infections) [<a href="#rid20">20</a>]. Similar to <em>E. faecium</em>, isolates of <em>E. faecalis </em>with elevated penicillin MICs have been associated with increased expression of the <em>pbp4 </em>gene (encoding a PBP homologous to PBP5 in <em>E. faecium</em>) and changes in the PBP4 amino acid sequence [<a href="#rid21">21,22</a>].</p><p>Enterococci are also intrinsically resistant to cephalosporins with a high MIC for the majority of these compounds; lower MICs are seen with newer cephalosporins, such as <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">ceftobiprole</a> and <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>. Intrinsic resistance to cephalosporins in <em>E. faecalis</em> is complex and has been tied to a number of proteins that impact cell wall synthesis. First, the presence of a putative serine-threonine kinase (designated IreK) is reciprocally regulated by IreP, a protein phosphatase whose gene is encoded immediately upstream of IreK<em> </em>[<a href="#rid23">23</a>]. A similar serine-threonine kinase system (designated Stk) has also been implicated in cephalosporin resistance in <em>E. faecium </em>[<a href="#rid24">24</a>]. Second, the two-component regulatory system CroRS (consisting of the histidine kinase CroS and the response regulator CroR) modulates cephalosporin resistance and has been tied to PBP4 expression in <em>E. faecalis </em>[<a href="#rid25">25</a>]. Finally, the low molecular weight PBP2a (a monofunctional transpeptidase) is also required for resistance to cephalosporins in both <em>E. faecalis </em>and <em>E. faecium </em>[<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H5"><span class="h1">AMINOGLYCOSIDE RESISTANCE</span><span class="headingEndMark"> — </span>Enterococci are intrinsically resistant to low to moderate levels of aminoglycosides. The minimum inhibitory concentration (MIC) of <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> is usually 8 to 64 mcg/mL and that of <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> is 64 to 512 mcg/mL, which makes aminoglycosides not active in vivo as monotherapy. However, synergism is generally seen with these two compounds when enterococci are exposed to a combination of the aminoglycoside with a cell wall active agent, such as penicillin or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>. In this setting, there is usually a marked increase in killing (&gt;100 colony-forming units [CFU]/mL, more killing than with penicillin alone), and a bactericidal effect (defined as ≥1000 CFU/mL or a 99.9 percent decrease from the starting inoculum) is achieved by 24 hours.</p><p>This synergistic effect presumably explains the clinical observation in the 1950s that a combination of penicillin with <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> was much more effective for treatment of enterococcal endocarditis than penicillin alone [<a href="#rid1">1</a>]. This regimen subsequently became the standard of care but has more recently been replaced by the combination of <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> plus <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'Enterococci'</a>.)</p><p>In addition to the usual increased MICs of aminoglycosides for all enterococci, a naturally occurring characteristic of <em>E. faecium</em> is higher MICs of <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> (MICs 64 to 1000 mcg/mL) and resistance to synergism with this aminoglycoside. This is due to the presence of an aminoglycoside-modifying enzyme, a tobramycin 6'-acetyltransferase [AAC(6')-Ii], which modifies tobramycin but not <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> [<a href="#rid29">29</a>]. This enzyme eliminates synergism between cell wall–active agents and tobramycin, kanamycin, netilmicin, and sisomicin. Similarly, many enterococci possess the <em>aph(3')-IIIa</em> gene, which confers high-level resistance to kanamycin and abolishes the synergistic effect of <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>. Therefore, with minor exceptions, gentamicin and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> are the only two aminoglycosides that should be considered to achieve synergistic therapy when treating enterococcal infections.</p><p class="headingAnchor" id="H6"><span class="h2">High-level resistance to streptomycin and gentamicin</span><span class="headingEndMark"> — </span>One of the more serious of the acquired resistances of enterococci is high-level resistance to both <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>. The significance of high-level resistance to these aminoglycosides is that it eliminates the synergism expected between gentamicin or streptomycin and a cell wall–active agent such as penicillin or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>. However, this significance has been lessened by reports of success of <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> plus <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> for therapy of <em>E. faecalis </em>endocarditis.</p><p>A striking report of this phenomenon in 1959 described an enterococcus from a patient with endocarditis that was not killed by the combination of penicillin and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> [<a href="#rid30">30</a>]. The patient had relapsing disease and was subsequently treated by penicillin plus <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a> (the only other aminoglycoside available at that time). While this combination produced a clinical cure, it also produced deafness and resulted in an article entitled "Deaf or dead" [<a href="#rid30">30</a>]. By 1970, a number of enterococcal isolates had acquired high-level resistance to streptomycin and to kanamycin.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">Streptomycin</a> resistance can be caused either by a ribosomal mutation, which leads to very high levels of resistance (MICs &gt;64,000 mcg/mL), or by the acquisition of a streptomycin-modifying enzyme (an adenylyltransferase), which usually produces MICs between 4000 and 16,000 mcg/mL (<a class="graphic graphic_table graphicRef57470" href="/z/d/graphic/57470.html" rel="external">table 1</a>) [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">Gentamicin</a> was found to be active against highly streptomycin- and kanamycin-resistant organisms and, by the mid-1970s, was being widely used for enterococcal endocarditis. However, since 1979, enterococci with high-level resistance to gentamicin have been increasingly reported [<a href="#rid32">32</a>]. This resistance is most often due to the production of an enzyme with two functional domains: one with 2''-phosphotransferase activity and one with 6'-acetyltransferase activity. These combined enzymatic activities result in high-level resistance and/or resistance to synergism to all commercially available aminoglycosides except <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>. The gene encoding this bifunctional enzyme, <em>aph(2'')-Ia/aac(6')-Ie</em>, is identical to a gene previously found in staphylococci (<a class="graphic graphic_table graphicRef57470" href="/z/d/graphic/57470.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The co-occurrence of high-level resistance to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and high-level resistance to <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> was reported in 1983, which documented, for the first time, strains of enterococci for which there was no known synergistic bactericidal regimen [<a href="#rid33">33</a>]. The addition of any aminoglycoside to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for such strains results in no more killing than ampicillin alone.</p><p></p><p>The Clinical Laboratory Standards Institute recommends screening of enterococci for high-level resistance to both <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> [<a href="#rid10">10</a>]. This is done by testing for growth at concentrations of 2000 mcg/mL and 500 mcg/mL of streptomycin and gentamicin, respectively, on brain heart infusion agar (BHI); when using BHI broth, the recommended concentration for streptomycin is 1000 mcg/mL. Alternatively, disks of gentamicin 120 mcg (correlates with 500 mcg/mL) and streptomycin 300 mcg (correlates with 1000 mcg/mL) on Mueller-Hinton agar can be used. If the results with the disk diffusion test are not conclusive, high-level resistance should be confirmed by other methods. Detection of high-level resistance to both these compounds precludes the use of available aminoglycosides for synergism in any clinical situation.</p><p>Four other gentamicin-resistance genes have been found that remain uncommon (<a class="graphic graphic_table graphicRef57470" href="/z/d/graphic/57470.html" rel="external">table 1</a>) [<a href="#rid34">34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One, designated <em>aph(2")-Ic</em>, was found in a veterinary isolate of <em>Enterococcus gallinarum</em> with a <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> MIC of 256 mcg/mL [<a href="#rid35">35</a>] and has been found in an occasional <em>E. faecium</em> and <em>E. faecalis</em> with intermediate-level resistance to gentamicin. The resulting enzyme is active against gentamicin and <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> but is not very active against netilmicin or <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second gene, <em>aph(2")-Id</em>, found in a few isolates of <em>Enterococcus casseliflavus</em> and <em>E. faecium</em>, confers high-level resistance to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, but the encoded enzyme is also not active against <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The third <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> resistance gene, <em>aph(2")-Ib</em>, found in <em>E. faecium</em>, was associated with MICs &gt;500 mcg/mL of gentamicin [<a href="#rid34">34</a>]. It also conferred resistance to synergism with most aminoglycosides other than <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A fourth gene encodes a 16S ribosomal RNA methyltransferase enzyme (designated EfmM) that appears to contribute to intrinsic aminoglycoside resistance in <em>E. faecium</em> [<a href="#rid36">36</a>].</p><p></p><p>The combination of <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>) with <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> is effective in the treatment of endocarditis due to isolates of <em>E. faecalis</em> exhibiting high-level resistance to all aminoglycosides [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'Enterococci'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">TRIMETHOPRIM-SULFAMETHOXAZOLE AND CLINDAMYCIN RESISTANCE</span><span class="headingEndMark"> — </span>Other resistances that appear to be naturally occurring traits of <em>E. faecalis</em> include low-level resistance to <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> due to the presence of <em>lsa </em>found in almost all strains [<a href="#rid37">37,38</a>] and in vivo resistance to <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, despite in vitro susceptibility to this combination [<a href="#rid39">39,40</a>].</p><p><a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">Trimethoprim</a> and sulfamethoxazole are both inhibitors of the synthesis of <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>, a necessary component for bacterial growth and survival. In vivo resistance of enterococci to <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> in animal models appears to be due to the fact that these organisms, unlike most other bacteria, can use preformed folic acid, that is, folic acid that is present in humans and animals. Acquired, high-level resistance is also seen in some enterococcal isolates.</p><p class="headingAnchor" id="H8"><span class="h1">VANCOMYCIN RESISTANCE</span><span class="headingEndMark"> — </span>Both high- and low-level resistance to glycopeptides can occur in enterococci. The definitions of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> susceptibility and resistance and the epidemiology of and infection control measures against vancomycin-resistant enterococci are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4045.html" rel="external">"Vancomycin-resistant enterococci: Epidemiology, prevention, and control"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Low-level resistance to vancomycin</span><span class="headingEndMark"> — </span>An intriguing intrinsic feature of two enterococcal species (<em>E. gallinarum</em> and <em>E. casseliflavus</em>) is their capacity to express low-level resistance to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (minimum inhibitory concentrations [MICs] 8 to 16 mcg/mL). This is due to the presence of a cluster of chromosomal genes involved in the synthesis of serine-ending peptidoglycan precursors (<em>vanC</em> and <em>vanT</em> genes, encoding a D-alanyl:D-serine ligase and a serine racemase, respectively) as well as destruction of the "normal" D-alanine–ending peptidoglycan (the <em>vanXYc</em> gene encoding a bifunctional D,D-peptidase/D,D-carboxypeptidase enzyme) [<a href="#rid41">41-43</a>].</p><p>The D-alanyl:D-serine ligase genes in both <em>E. gallinarum</em> and in <em>E. casseliflavus</em> (<em>vanC-1</em> and <em>vanC-2</em>) are specific for these species and can be used to differentiate them from each other and from other enterococcal species [<a href="#rid44">44,45</a>]. A third putative species, <em>E. flavescens</em>, has a gene that is almost identical to <em>vanC-2</em>, and many consider it the same species as <em>E. casseliflavus</em> [<a href="#rid45">45</a>].</p><p>Many isolates of these species test susceptible to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> in vitro and even those that express resistance more fully are usually inhibited by 32 mcg/mL of vancomycin. This low level of resistance is explained by the fact that the D-alanyl-D-serine terminus of peptidoglycan precursors has moderately reduced affinity for vancomycin [<a href="#rid46">46</a>]. Some acquired <em>van</em> gene clusters can also confer low-level resistance to vancomycin by synthesizing peptidoglycan precursors ending in D-serine. These particular phenotypes include VanE, VanG, VanL, and VanN (<a class="graphic graphic_table graphicRef83403" href="/z/d/graphic/83403.html" rel="external">table 2</a>) [<a href="#rid47">47-50</a>].</p><p class="headingAnchor" id="H10"><span class="h2">High-level resistance to vancomycin</span><span class="headingEndMark"> — </span>High-level <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance is the most problematic resistance of enterococci because it often appears in strains already highly resistant to <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> (primarily <em>E. faecium</em>). (See  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections"</a>.)</p><p>Despite our awareness of the propensity of enterococci to acquire antibiotic resistance, the emergence of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance in the late 1980s was unanticipated. The surprise derived largely from the fact that vancomycin had been commercially available for over thirty years without high-level resistance ever being seen. However, the drug did not begin to receive substantial clinical use until the late 1970s and early 1980s when methicillin-resistant <em>S. aureus</em>, methicillin-resistant coagulase-negative staphylococci, and <em>Clostridioides</em> <em>difficile</em> became pathogens of major concern in the United States.</p><p>When one examines the complex nature of the mechanism of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance and the diverse number of vancomycin-resistance gene clusters, it seems most likely that resistance arose in the distant past, perhaps in response to glycopeptides (which are natural products) present in the environment, and has now been selected for in clinically relevant organisms by the commercial use of glycopeptide antibiotics, including the use of avoparcin in the past in animal feeds in the European Union and elsewhere. Consistent with this hypothesis is the identification of soil organisms (<em>Paenibacillus thiaminolyticus</em> and <em>P. apiarius</em>) that harbor vancomycin-resistance genes that are almost identical to those of enterococci [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Mechanism of high-level resistance to vancomycin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> inhibits enterococci by binding to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of cell wall precursors, compromising the subsequent enzymatic steps in the synthesis of the cell wall. High-level resistance to vancomycin is encoded by different clusters of genes referred to as the vancomycin-resistance gene clusters (eg, <em>vanA</em>, <em>B</em>, <em>D</em>, and <em>M</em> gene clusters).</p><p>The end result is the replacement of D-Ala-D-Ala–ending peptidoglycan precursors with D-alanyl-D-lactate termini [<a href="#rid46">46</a>]. The replacement of D-alanine by D-lactate, which disrupts one of the five hydrogen bonds required for the interaction of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> with its target, decreases the binding affinity of this antibiotic almost 1000-fold.</p><p>The three major phenotypes, VanA, VanB, and VanD, can sometimes be differentiated by the level of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance, susceptibility to the glycopeptide antibiotic teicoplanin, and whether the resistance is induced by exposure to teicoplanin (<a class="graphic graphic_table graphicRef83403" href="/z/d/graphic/83403.html" rel="external">table 2</a>) [<a href="#rid52">52</a>]. Accurate discrimination of these phenotypes can be achieved by identification of the corresponding genes using polymerase chain reaction (PCR) or hybridization techniques [<a href="#rid53">53</a>].</p><p>VanF is a phenotype described in <em>Paenibacillus popilliae</em>, a biopesticidal agent used in agriculture. The <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance gene cluster (<em>vanF</em>) has 77 percent identity with the <em>vanA</em> gene cluster, and it has been postulated that these genes were originally transferred from <em>P. popilliae</em> to enterococci [<a href="#rid54">54</a>]. Other members of the <em>Paenibacillus</em> and <em>Rhodococcus</em> family also harbor genes homologous to <em>vanA</em> [<a href="#rid55">55</a>].</p><p>VanA is the most common type of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance, usually mediates higher levels of resistance than other types, and causes cross-resistance to teicoplanin. The <em>vanA</em> gene cluster is typically found on a transposon identical or related to Tn1546, which, in turn, is often found within a plasmid [<a href="#rid52">52</a>]. The <em>vanA</em> cluster has disseminated to other bacterial species, including clinical isolates of methicillin-resistant <em>S. aureus</em> (MRSA). Several isolates of these vancomycin-resistant <em>S. aureus</em> have been reported in various countries. (See  <a class="medical medical_review" href="/z/d/html/3165.html" rel="external">"Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin", section on 'Vancomycin-resistant S. aureus'</a>.)</p><p>These findings emphasize the fact that vancomycin-resistance gene clusters can overcome the species barrier and disseminate to several bacterial species, limiting the therapeutic options even further.</p><p class="headingAnchor" id="H12"><span class="h3">VanA phenotype</span><span class="headingEndMark"> — </span>The genes encoding the VanA phenotype (<em>vanS</em>, <em>R</em>, <em>H</em>, <em>A</em>, <em>X</em>, <em>Y</em>, <em>Z</em>) have been best studied [<a href="#rid52">52,56</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The <em>vanS</em> and <em>vanR</em> genes encode a two-component regulatory system that is involved in the induction of expression of resistance. VanS is likely to sense an alteration of the cell envelope caused by <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and then signals to the response regulator, VanR, to turn on the expression of three genes, <em>vanA</em>, <em>vanH</em>, and <em>vanX</em>, which are necessary and sufficient for resistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VanH (encoded by the gene <em>vanH</em>) is a dehydrogenase that generates significant quantities of D-lactate for peptidoglycan synthesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VanA (encoded by the <em>vanA</em> gene) is a ligase that catalyzes the binding of D-alanine to D-lactate (the corresponding ligases in other types are VanB, VanD, VanF, and VanM), resulting in the formation of D-alanyl-D-lactate. This dipeptide is then added by endogenous enterococcal enzymes to a tripeptide cell wall precursor. As a consequence, a pentapeptide precursor ending in D-Ala-D-Lac (pentadepsipeptide) is synthesized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The formation of a D-Ala-D-Lac–containing precursor is not sufficient to cause resistance to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> if the cell continues to produce the normal cell wall precursor ending in D-Ala-D-Ala. VanX and VanY complete the resistance phenotype. VanX is a D,D-dipeptidase that cleaves D-Ala-D-Ala [<a href="#rid57">57</a>]. Any D-Ala-D-Ala dipeptide that escapes this dipeptidase activity and is incorporated into peptidoglycan precursors is removed by VanY. VanY is a D,D-carboxypeptidase, which cleaves the terminal D-Ala from the cell wall precursor, leaving a tetrapeptide precursor that can be utilized for cell wall synthesis but to which vancomycin does not bind [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The function encoded by <em>vanZ</em> is not known, although, when cloned alone, it confers teicoplanin resistance onto the host strain, and has been associated with increases in the MIC of other lipoglycopeptide antibiotics including <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">dalbavancin</a> and <a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">oritavancin</a> [<a href="#rid58">58-60</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h3">VanB phenotype</span><span class="headingEndMark"> — </span>The VanB phenotype, the second most common type, is less frequently encountered than VanA. Some enterococci with this phenotype will be missed if concentrations of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> used for screening are too high (&gt;20 mcg/mL) (<a class="graphic graphic_table graphicRef83403" href="/z/d/graphic/83403.html" rel="external">table 2</a>).</p><p>The major phenotypic difference between VanA- and VanB-producing strains is that teicoplanin is not a good inducer of expression of the genes in the <em>vanB</em> cluster; as a result, <em>vanB</em>-containing bacteria usually test teicoplanin susceptible. However, mutations can and do occur spontaneously within the <em>vanB</em> cluster that result in teicoplanin-resistant derivatives.</p><p>Most of the genes in the <em>vanB</em> gene cluster have homologs to genes in the <em>vanA</em> cluster and appear to function in a similar manner to produce a cell wall precursor ending in D-Ala-D-Lac. However, the <em>vanB</em> gene cluster has a distinct gene, <em>vanW</em>, it has no <em>vanZ</em>, and its <em>vanY</em> gene is in a different location. Although this phenotype was originally reported as nontransferable, there are now a number of reports of strain to strain transfer of the <em>vanB</em> gene cluster as part of large (90 to 250 kb) chromosomally located mobile elements and as part of plasmids. The <em>vanB</em> gene cluster has been observed in <em>Streptococcus gallolyticus</em> [<a href="#rid61">61</a>] and in anaerobic bacteria (<em>Eggerthella lenta</em> and <em>Clostridium inoculum</em>) [<a href="#rid62">62</a>].</p><p>Some isolates of <em>E. faecium</em> that carry the <em>vanA</em> gene cluster but express the VanB phenotype have been described in Southeast Asia [<a href="#rid63">63</a>]. These isolates usually harbor insertions or deletions in the <em>vanY</em>, <em>vanX</em>, <em>vanZ</em>, or <em>vanR</em> genes.</p><p class="headingAnchor" id="H14"><span class="h2">Vancomycin dependence</span><span class="headingEndMark"> — </span>An interesting variation of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance is that of vancomycin dependence. Vancomycin-dependent enterococci (VDE) evolve from vancomycin-resistant strains, usually from those that contain the <em>vanB</em> gene cluster. These organisms have lost the ability to make their native cell wall, which contains D-Ala-D-Ala termini; as a result, they are dependent upon the continued production of peptidoglycan termini containing D-Ala-D-Lac. Because the vancomycin-resistance genes are normally inducible, the D-Ala-D-Lac–ending peptidoglycan is synthesized only when vancomycin is present (eg, in a patient receiving vancomycin therapy or when vancomycin is added to the in vitro culture medium).</p><p>A number of patients have been described with VDE that appear to have negative cultures, unless the samples are cultivated in the presence of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid64">64</a>]. In one instance, blood cultures, drawn while the patient was on vancomycin, grew in the initial blood culture bottle but failed to grow on subculture, except around a vancomycin antibiotic disk. Although stopping vancomycin therapy may be of temporary benefit, VDE can revert to non-dependence but are still vancomycin resistant. They can revert by either becoming constitutive producers of the D-Ala-D-Lac–containing cell wall by a mutation that restores the activity of the intrinsic D-Ala:D-Ala ligase or by mutations in the transcriptional terminator region of the regulatory genes, resulting in expression of the resistance genes in the absence of vancomycin [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H15"><span class="h1">LINEZOLID RESISTANCE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> is active against gram-positive bacteria, including enterococci and staphylococci. Its mechanism of action involves the inhibition of protein synthesis by interactions within the 50S ribosomal subunit [<a href="#rid67">67</a>]. Linezolid interferes with the positioning of the aminoacyl-tRNA in the A site of the bacterial ribosomes [<a href="#rid68">68</a>].</p><p><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> resistance has been reported in clinical isolates of both staphylococci and enterococci [<a href="#rid69">69-72</a>]. In enterococci, the G2576U (<em>Escherichia coli</em>–numbering scheme) mutation in domain V of the 23S rRNA is the most common mutation associated with resistance [<a href="#rid72">72-74</a>]. Since bacteria carry several copies of the 23S rRNA gene, the number of rRNA genes mutated appears to be an important determinant of resistance (gene dosage effect); the minimum inhibitory concentration (MIC) increases in proportion to the number of mutated genes [<a href="#rid74">74,75</a>]. The linezolid dose and length of treatment influences the number of mutated genes and the resistance phenotype [<a href="#rid74">74</a>].</p><p>Subsequently, plasmid-mediated resistance to <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> was described in United States human clinical isolates of staphylococci [<a href="#rid76">76</a>]. The mechanism of resistance involves the methylation of an adenine at position 2503 (A2503) of the 23S rRNA. This modification is carried out by a methyltransferase (designated <em>cfr</em>, for chloramphenicol-florfenicol resistance) [<a href="#rid77">77,78</a>]. The <em>cfr</em> gene was previously found in the chromosome of a methicillin-resistant <em>S. aureus</em> (MRSA) strain recovered from the sputum of a patient who died of a nosocomial pneumonia in Colombia [<a href="#rid79">79</a>]; analysis of DNA from the <em>cfr</em> region of the Colombian isolate suggested that the MRSA strain may have acquired this gene through an enterococcal donor [<a href="#rid77">77</a>]. Furthermore, the <em>cfr</em> gene has been described in a clinical isolate of <em>E. faecalis</em> from animal origin in China and on a transferable plasmid from a human isolate of <em>E. faecalis</em> recovered from a patient in Thailand [<a href="#rid80">80,81</a>]. Two variants of <em>cfr </em>(A and B) have been described in enterococci.</p><p>A transferable gene encoding a protein with an adenosine triphosphate (ATP)-binding cassette motif, <em>optrA</em>, has been found to confer resistance to <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>. The gene was found in animal and human isolates of enterococci (<em>E. faecalis</em> and <em>E. faecium</em>) from China. The <em>optrA</em> gene belongs to the family of ATP-binding proteins; these proteins confer resistance by a ribosomal protection mechanism, interacting with the ribosome and displacing antibiotic from its target [<a href="#rid38">38,82,83</a>]. A somewhat related gene reported in enterococci, <em>poxtA, </em>also appears to mediate ribosomal protection against oxazolidinones. </p><p>Oxazolidinone resistance among enterococcal isolates has been increasingly documented [<a href="#rid84">84-86</a>]. <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> resistance was initially described sporadically, and it was associated with prolonged use of the antibiotic [<a href="#rid70">70</a>]. In a study from Chicago, linezolid-resistant vancomycin-resistant enterococci (VRE) was described in five patients (four renal transplant recipients), usually after more than 21 days of therapy and often in patients who had received several courses of other antimicrobials [<a href="#rid69">69</a>].</p><p>Horizontal spread of specific linezolid-resistant outbreak strains has been described [<a href="#rid85">85,86</a>]. In one study, the risk factors associated with the acquisition of linezolid-resistant enterococci (LRE) included administration of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> and/or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, peripheral vascular disease, total <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>, and receipt of a solid organ transplant [<a href="#rid84">84</a>]. Although it is evident that the emergence of <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> resistance is associated with the heavy use of this antibiotic, LRE have been isolated from patients without previous exposure to the antibiotic [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H16"><span class="h1">DAPTOMYCIN RESISTANCE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is a cyclic semisynthetic lipopeptide antibiotic that is active against a wide variety of gram-positive bacteria. It has potent bactericidal activity mainly due to its ability to penetrate the bacterial cell wall and insert into the cytoplasmic membranes in a calcium-dependent manner. Daptomycin appears to target the membrane (interacting with phosphatidylglycerol [PG], a cell-membrane phospholipid) with preference for the bacterial septum causing alterations in cell division, cell membrane architecture, and function [<a href="#rid88">88,89</a>]. Data suggest that daptomycin interacts with bactoprenol intermediates of lipid II in the presence of PG at the membrane level, altering peptidoglycan synthesis [<a href="#rid90">90</a>]. Further, daptomycin appears to directly affect enzymes involved in cell membrane and cell wall metabolism, displacing them from the inner leaflet of the cell membrane [<a href="#rid91">91</a>].</p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> has been used successfully for the treatment of a variety of VRE infections, including bone, joint, and soft tissue infections [<a href="#rid92">92</a>], bacteremia [<a href="#rid93">93</a>], and endocarditis [<a href="#rid94">94</a>]. Retrospective studies suggest that daptomycin may be associated with better clinical outcomes than <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> in the treatment of VRE bacteremia [<a href="#rid95">95,96</a>].</p><p>Resistance to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> has been reported increasingly in enterococci, including isolates from patients who have never received the drug [<a href="#rid97">97-100</a>]. Several mutations have been associated with development of resistance, suggesting that distinct genetic pathways are responsible for this phenotype. Initial insights into the mechanisms of daptomycin resistance in enterococci have been provided by studies using whole genome sequencing of both <em>E. faecalis</em> and <em>E. faecium</em> isolates recovered from patients before and after daptomycin therapy [<a href="#rid101">101,102</a>]. Enterococci employ two main strategies to become resistant to daptomycin, namely, diversion of the antibiotic from the septal target of the antibiotic (characteristic of <em>E. faecalis</em>) and "repulsion" of the antibiotic molecule from the cell surface impairing the interaction of the drug with the cell membrane (commonly observed with <em>E. faecium</em>) [<a href="#rid103">103,104</a>].</p><p>Several genes that have been associated with development of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> resistance may be grouped in two categories: genes that code for regulatory systems that control the cell envelope stress response to antibiotics and antimicrobial peptides and genes encoding enzymes involved in phospholipid metabolism. One protein named LiaX, a component of the LiaFSR regulatory system, plays an important role in sensing and activating the stress-response system in the presence of daptomycin and antimicrobial peptides [<a href="#rid105">105</a>].</p><p>Failure of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> monotherapy in the treatment of VRE endocarditis without evident development of resistance (ie, lack of increase in minimum inhibitory concentration) has been well documented [<a href="#rid106">106</a>]. Two strategies have been attempted to prevent emergence of resistance:</p><p class="bulletIndent1"><span class="glyph">●</span>The first strategy involves the use of higher doses of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> than 6 mg/kg intravenously (IV) every 24 hours (which is the dose approved by the US Food and Drug Administration for treatment of <em>S. aureus</em> bacteremia). Since enterococci are less susceptible to daptomycin than <em>S. aureus</em>, some experts recommend the use of higher doses (10 to 12 mg/kg IV every 24 hours) to treat severe deep-seated enterococcal infection [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second strategy involves combination of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> with beta-lactams, taking advantage of the see-saw effect (increased susceptibility to beta-lactams when cells become resistant to daptomycin), or other antimicrobial agents. Persistent bacteremia due vancomycin-resistant <em>E. faecalis</em> and <em>E. faecium</em> (which failed daptomycin monotherapy at high dose) has been cleared with the combination of daptomycin plus <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> (<em>E. faecalis</em>) and daptomycin plus <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> (<em>E. faecium</em>) [<a href="#rid94">94,107</a>]. Furthermore, in vitro data suggest that the beta-lactam may increase daptomycin binding to the cell membrane and further clinical data are needed.</p><p></p><p class="headingAnchor" id="H3068674752"><span class="h1">RESISTANCE TO TETRACYCLINE AND NEWER GENERATION TETRACYCLINE DERIVATIVES</span><span class="headingEndMark"> — </span>Resistance to <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> antibiotics in enterococci is common, and is mediated by drug efflux pumps encoded by <em>tet</em>(K) and <em>tet</em>(L) or ribosomal protection factors which recycle the stalled ribosome complex encoded by <em>tet</em>(M), <em>tet</em>(O), and <em>tet</em>(S) [<a href="#rid108">108</a>]. Several other tetracycline derivatives are now available in clinical practice, including <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a>, and <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">eravacycline</a>, which typically retain activity against tetracycline resistant bacterial isolates, including enterococci. These compounds are typically poor substrates for tetracycline efflux pumps and ribosomal protection factors. However, reports of <em>tet</em>(L) and <em>tet</em>(M) gene copy number expansion and subsequent hyperproduction of the efflux pump and ribosomal protection factor leading to tigecycline resistance have been reported in clinical isolates of <em>E. faecium </em>[<a href="#rid109">109</a>].</p><p>Although reports of resistance are still uncommon, it appears that modification of the binding site is the primary mechanism of resistance for these other <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> derivatives. This can occur either by mutations in the genes encoding the ribosomal RNA, or those arising in the <em>rpsJ</em> gene, which encodes the S10 protein of the 30S ribosomal subunit [<a href="#rid110">110,111</a>]. Changes in the S10 protein cluster at the end of a long peptide loop whose end is near the drug binding site on the 16S rRNA [<a href="#rid112">112</a>]. These changes are likely to affect the binding pocket and alter the affinity of the drug for the target site. </p><p class="headingAnchor" id="H19"><span class="h1">DETECTION OF ANTIBIOTIC RESISTANCE</span><span class="headingEndMark"> — </span>Because of the difficulty in detecting some resistances of enterococci using standard laboratory methods, several special tests are recommended for these organisms.</p><p class="headingAnchor" id="H20"><span class="h2">Beta-lactam resistance</span><span class="headingEndMark"> — </span>Nitrocefin, a specific beta-lactamase test, is recommended for detecting the rare beta-lactamase-producing <em>Enterococcus </em>among isolates from endocarditis and other serious infections [<a href="#rid113">113</a>]. Susceptibility testing at a high inoculum is also effective at detecting penicillin and <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> resistance since more enzymes will be present; as noted above, these organisms will generally not appear resistant when tested at the standard inoculum. (See <a class="local">'Beta-lactam resistance'</a> above.)</p><p class="headingAnchor" id="H21"><span class="h2">Vancomycin resistance</span><span class="headingEndMark"> — </span>To detect <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance, enterococci can be inoculated onto brain-heart infusion (BHI) agar containing vancomycin 6 mcg/mL, followed by incubation for 24 hours at 35ºC. This screening test should detect <em>vanA</em>- and most <em>vanB</em>-containing enterococci but may also detect some organisms with the <em>vanC</em> phenotype. If minimum inhibitory concentrations (MICs) are determined, incubation for a full 24 hours is recommended (rather than 16 to 20 hours, which is commonly used) with careful examination for even faint growth [<a href="#rid113">113</a>]. For isolates intermediate in susceptibility (MIC 8 to 16 mcg/mL), identification to the species level is suggested by the Clinical Laboratory Standards Institute to identify the intrinsically resistant species, <em>E. casseliflavus</em> and <em>E. gallinarum</em>.</p><p class="headingAnchor" id="H22"><span class="h3">Vancomycin dependence</span><span class="headingEndMark"> — </span>Vancomycin-dependent enterococci (VDE) may be detected by incorporating <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (eg, 6 mcg/mL) into BHI or agar or by adding a disk to an agar surface. Commercial agar for detection of vancomycin-resistant enterococci (VRE) will suffice.</p><p class="headingAnchor" id="H23"><span class="h2">Aminoglycoside resistance</span><span class="headingEndMark"> — </span>For aminoglycoside testing, BHI agar with 500 mcg/mL of <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> or 2000 mcg/mL of <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> or BHI broth with 500 mcg/mL of gentamicin or 1000 mcg/mL of streptomycin is recommended to detect resistance to synergism. For streptomycin-containing media, if there is no growth at 24 hours, plates or wells should be re-incubated for an additional 24 hours. Paper disks containing large quantities of aminoglycosides are commercially available in Europe but have not yet been approved in the United States.</p><p>Most enterococci with high-level resistance to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> grow just as well on 2000 mcg/mL as on 500 mcg/mL, but 500 mcg/mL is used because it is sufficient to differentiate intrinsically resistant enterococci (MICs &lt;64 mcg/mL) from strains with acquired resistance, and it is less costly since it uses less reagent.</p><p>For <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a>, MICs of intrinsically resistant strains can be as high as 256 to 512 mcg/mL; as a result, higher concentrations must be used to distinguish acquired from intrinsic resistance to this drug. However, 2000 mcg/mL in broth has failed to support adequate growth of some resistant strains due to production of streptomycin adenylyltransferase; this observation has led to the use of 1000 mcg/mL in this medium. BHI medium is recommended because it better supports growth than Mueller-Hinton medium.</p><p>Aminoglycosides other than <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> or <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> need not be tested. Furthermore, the results may be misleading. As an example, MICs of <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> cannot distinguish intrinsically resistant strains from strains that have acquired the kanamycin-neomycin phosphotransferase, which causes resistance to synergism with amikacin. In addition, difficulties with <em>E. faecium</em> and <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> were described above; strains of this species produce tobramycin 6'-acetyltransferase, which modifies tobramycin but not gentamicin [<a href="#rid29">29</a>] and should be considered resistant to synergism with tobramycin. (See <a class="local">'Aminoglycoside resistance'</a> above.)</p><p>One word of caution relates to strains with intermediate <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> resistance mediated by the newly described gene <em>aph(2'')-Ic</em>, which confers resistance to synergism with gentamicin [<a href="#rid35">35</a>]. Strains described to date showed growth of 1 to 15 colonies on agar plates with 500 mcg/mL of gentamicin. This is far less than the confluent growth usually observed with strains with high-level resistance to gentamicin and may therefore be overlooked. In addition, this enzyme did not seem to interfere with synergism with netilmicin, unlike the bifunctional enzyme. Similarly, <em>aph(2")-Id</em> is not active against <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H24"><span class="h2">Resistance differences related to species</span><span class="headingEndMark"> — </span>A characteristic of <em>E. faecium</em> that is not detected by routine antimicrobial testing is the intrinsic resistance of members of this species to synergism between cell wall–active agents and <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>. There is no established clinical laboratory test to identify this property except for identification of the species or performance of time-kill curves.</p><p>An expanded-range MIC determination might be helpful. However, concentrations of <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> would have to be higher than those used for other organisms, and it would not be practical for clinical laboratories to have such a test available, particularly since alternative aminoglycosides can be used and their resistance can be detected by routine methods. A gene probe to detect the gene [<em>aac(6')-Ii</em>] responsible for resistance to tobramycin synergism [<a href="#rid29">29</a>] has been used as a reliable method for identifying <em>E. faecium</em> with this property [<a href="#rid114">114</a>].</p><p>Another characteristic species difference is that higher levels of resistance to penicillins and carbapenems are typically seen in <em>E. faecium</em> and <em>E. raffinosus</em> (which is very similar biochemically to <em>E. avium</em>) compared with other enterococcal species. This resistance is almost <strong>never</strong> due to beta-lactamase production, which is uncommon in general in enterococci and is extremely rare in non–<em>E. faecalis</em>.</p><p class="headingAnchor" id="H25"><span class="h3">E. gallinarum and E. casseliflavus</span><span class="headingEndMark"> — </span>The potential of <em>E. gallinarum</em> and <em>E. casseliflavus</em> to express low-level resistance to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> is another characteristic difference among enterococcal species. Whether members of these species that test susceptible to vancomycin can be adequately treated by this antibiotic is not known; however, since they are typically susceptible to penicillin and <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, the use of one of these agents would be more prudent.</p><p>The recovery of <em>E. gallinarum</em> and <em>E. casseliflavus</em> strains with low-level <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance is not an indication for isolation of the patient, since the intrinsic resistance is not found on plasmids or transposons that might spread to other bacteria. Nonetheless, the description of a hospital-wide outbreak caused by a strain of <em>E. gallinarum</em> suggests that isolation may be useful when dissemination of a virulent strain is suspected [<a href="#rid115">115</a>].</p><p>Although <em>vanA</em>, which has propensity to be on transferable elements, has appeared in both <em>E. gallinarum</em> and <em>E. casseliflavus</em>, transmission of infection has been rare. The presence of <em>vanA</em> in <em>E. gallinarum</em> causes higher levels of resistance than seen with the VanC phenotype, as well as resistance to teicoplanin [<a href="#rid116">116</a>]. As a result, the presence of <em>vanA</em> can be distinguished from the intrinsic low-level VanC-resistant phenotype.</p><p>VanB, which can also cause low-level <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance, has not been reported in either of these two species.</p><p class="headingAnchor" id="H26"><span class="h2">Daptomycin resistance</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> requires the presence of physiologic levels of calcium ions (50 mcg/mL) for maximum activity. As a result, the Clinical Laboratory Standards Institute recommends only the broth dilution method with Mueller-Hinton broth adjusted to a final calcium ion concentration of 50 mg/L [<a href="#rid113">113</a>]. Calcium-supplemented daptomycin Etest strips also appear to be an accurate method to detect daptomycin resistance, although there are discrepancies with results obtained by broth microdilution [<a href="#rid117">117</a>]. </p><p>Nonetheless, data suggest that MIC determination for <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> by both broth microdilution and Etest is unreliable, with poor interlaboratory reproducibility [<a href="#rid118">118</a>]. Furthermore, controversies exist in the breakpoint for daptomycin. For <em>E. faecium</em>, susceptibility (broth microdilution) should be interpreted as follows: (1) susceptible dose-dependent: MIC &lt;4 mcg/mL and (2) resistant: MIC &gt;8 mcg/mL (note that there is no “susceptible” category). For <em>E. faecalis</em> the breakpoints are &lt;2, 4, and &gt;8 mcg/ml, for susceptible, intermediate, and resistant, respectively. Despite these changes and due to the inaccuracy of the tests, clinical judgment should be exercised when treating "daptomycin-susceptible" enterococcal bacteremia and other deep-seated infections with this antibiotic.</p><p class="headingAnchor" id="H95066433"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics of resistance in enterococci – </strong>Enterococci can develop resistance through mutations as well as acquisition of new genes on plasmids and transposons that can cross species and genera. Many of the acquired resistances likely emerged among enterococci colonizing humans or animals that were given antibiotics for other reasons. (See <a class="local">'Genetics of resistance in enterococci'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-lactam resistance – </strong>Enterococci have intrinsic resistance to many beta-lactam compounds, particularly cephalosporins. <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">Ampicillin</a> resistance in <em>Enterococcus faecalis,</em> albeit very rare, can be caused by penicillinase, which can be overcome with the addition of a beta-lactamase inhibitor. <em>Enterococcus faecium</em> is intrinsically resistant to ampicillin due to the presence of a low-affinity penicillin-binding protein, can become more highly resistance via amino acid changes and increased expression of <em>pbp5</em>, and thus is not susceptible to beta-lactamase-inhibitor combinations. (See <a class="local">'Beta-lactam resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminoglycoside resistance – </strong>Enterococci have intrinsic low to moderate level resistance to aminoglycosides, but <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">streptomycin</a> retain synergistic activity against enterococci when combined with a cell wall agent. When high-level resistance to one of these aminoglycosides is present (eg, through ribosomal mutations or acquisition of modifying enzymes), the synergistic effect of that agent is eliminated. (See <a class="local">'Aminoglycoside resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a><strong> and </strong><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a><strong> resistance – </strong>Although enterococci may be susceptible in vitro to trimethoprim-sulfamethoxazole, they seem to be resistant in vivo due to their capacity to utilize preformed <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>. (See <a class="local">'Trimethoprim-sulfamethoxazole and clindamycin resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a><strong> resistance – </strong>Resistance to vancomycin develops through alteration of its binding site, the D-alanyl-D-alanine terminus of peptidoglycan precursors. Production of D-alanyl-D-lactate–ending peptidoglycans, for which vancomycin has significantly reduced affinity, confers high-level vancomycin resistance, primarily seen in <em>E. faecium</em>. The vancomycin-resistance gene clusters that encode high-level resistance can disseminate to other bacterial species. (See <a class="local">'Vancomycin resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a><strong> resistance – </strong>Enterococcal resistance to linezolid is acquired through mutations and modifications of ribosomal RNA and proteins. The emergence of resistance is generally associated with the use of linezolid, although resistant enterococci have been isolated from patients without previous exposure to the antibiotic. The emergence of linezolid resistance in enterococci through transferable plasmids carrying <em>cfr</em> and other genes (<em>optrA</em> and <em>poxtA</em>) raises concern of spreading linezolid resistance to other strains and species. (See <a class="local">'Linezolid resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a><strong> resistance – </strong>Resistance to daptomycin has been reported both after antibiotic exposure and in the absence of drug administration. The mechanism of resistance involves mutations in genes associated with the regulation of the cell envelope response to antibiotics and cell membrane phospholipid metabolism, among others. Clinical failure of daptomycin in the setting of infection with enterococci exhibiting apparent in vitro susceptibility to the drug has been described; results of minimum inhibitory concentration tests should be interpreted with caution due to poor reproducibility of the test. (See <a class="local">'Daptomycin resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance to tetracyclines and other </strong><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a><strong> derivatives</strong> – Resistance to tetracyclines is common in enterococci and occurs due to tetracycline efflux pumps or ribosomal protection factors. Resistance to newer generation tetracycline derivatives such as <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a>, and <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">eravacycline</a>, is associated with changes in the <em>rpsJ</em> gene encoding the S10 protein of the 30S ribosomal subunit. These changes are likely to alter the drug binding pocket and may act in concert with overexpression of traditional resistance determinants such as drug efflux pumps.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">GERACI JE, MARTIN WJ. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases. Circulation 1954; 10:173.</a></li><li><a class="nounderline abstract_t">Hodges TL, Zighelboim-Daum S, Eliopoulos GM, et al. Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother 1992; 36:121.</a></li><li><a class="nounderline abstract_t">Dunny GM, Leonard BA, Hedberg PJ. Pheromone-inducible conjugation in Enterococcus faecalis: interbacterial and host-parasite chemical communication. J Bacteriol 1995; 177:871.</a></li><li><a class="nounderline abstract_t">Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990; 3:46.</a></li><li><a class="nounderline abstract_t">Clewell DB, Gawron-Burke C. Conjugative transposons and the dissemination of antibiotic resistance in streptococci. Annu Rev Microbiol 1986; 40:635.</a></li><li><a class="nounderline abstract_t">Roberts MC. Characterization of the Tet M determinants in urogenital and respiratory bacteria. Antimicrob Agents Chemother 1990; 34:476.</a></li><li><a class="nounderline abstract_t">Manson JM, Hancock LE, Gilmore MS. Mechanism of chromosomal transfer of Enterococcus faecalis pathogenicity island, capsule, antimicrobial resistance, and other traits. Proc Natl Acad Sci U S A 2010; 107:12269.</a></li><li><a class="nounderline abstract_t">Murray BE. Beta-lactamase-producing enterococci. Antimicrob Agents Chemother 1992; 36:2355.</a></li><li><a class="nounderline abstract_t">Sarti M, Campanile F, Sabia C, et al. Polyclonal diffusion of beta-lactamase-producing Enterococcus faecium. J Clin Microbiol 2012; 50:169.</a></li><li class="breakAll">Clinical Laboratory Standards Institute. Performance standards for antimicrobial testing: Twentieth informational supplement. Document M100-S20, Clinical Laboratory Standards Institute; 2023.</li><li><a class="nounderline abstract_t">Grayson ML, Eliopoulos GM, Wennersten CB, et al. Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 1991; 35:2180.</a></li><li><a class="nounderline abstract_t">Fontana R, Ligozzi M, Pittaluga F, Satta G. Intrinsic penicillin resistance in enterococci. Microb Drug Resist 1996; 2:209.</a></li><li><a class="nounderline abstract_t">Galloway-Peña JR, Rice LB, Murray BE. Analysis of PBP5 of early U.S. isolates of Enterococcus faecium: sequence variation alone does not explain increasing ampicillin resistance over time. Antimicrob Agents Chemother 2011; 55:3272.</a></li><li><a class="nounderline abstract_t">Rice LB, Bellais S, Carias LL, et al. Impact of specific pbp5 mutations on expression of beta-lactam resistance in Enterococcus faecium. Antimicrob Agents Chemother 2004; 48:3028.</a></li><li><a class="nounderline abstract_t">Mainardi JL, Legrand R, Arthur M, et al. Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium. J Biol Chem 2000; 275:16490.</a></li><li><a class="nounderline abstract_t">Mainardi JL, Morel V, Fourgeaud M, et al. Balance between two transpeptidation mechanisms determines the expression of beta-lactam resistance in Enterococcus faecium. J Biol Chem 2002; 277:35801.</a></li><li><a class="nounderline abstract_t">Conceição N, da Silva LE, Darini AL, et al. Penicillin-resistant, ampicillin-susceptible Enterococcus faecalis of hospital origin: pbp4 gene polymorphism and genetic diversity. Infect Genet Evol 2014; 28:289.</a></li><li><a class="nounderline abstract_t">Infante VH, Conceição N, de Oliveira AG, Darini AL. Evaluation of polymorphisms in pbp4 gene and genetic diversity in penicillin-resistant, ampicillin-susceptible Enterococcus faecalis from hospitals in different states in Brazil. FEMS Microbiol Lett 2016; 363.</a></li><li><a class="nounderline abstract_t">Ono S, Muratani T, Matsumoto T. Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis. Antimicrob Agents Chemother 2005; 49:2954.</a></li><li><a class="nounderline abstract_t">Cabrera NL, Malek AE, Aitken SL, Arias CA. Outcomes of Patients with Bloodstream Infections Caused by Ampicillin-Susceptible but Penicillin-Resistant Enterococcus faecalis: Caution in Interpreting the Results. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Kim D, Lee H, Yoon EJ, et al. Prospective Observational Study of the Clinical Prognoses of Patients with Bloodstream Infections Caused by Ampicillin-Susceptible but Penicillin-Resistant Enterococcus faecalis. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Rice LB, Desbonnet C, Tait-Kamradt A, et al. Structural and Regulatory Changes in PBP4 Trigger Decreased β-Lactam Susceptibility in Enterococcus faecalis. mBio 2018; 9.</a></li><li><a class="nounderline abstract_t">Kristich CJ, Wells CL, Dunny GM. A eukaryotic-type Ser/Thr kinase in Enterococcus faecalis mediates antimicrobial resistance and intestinal persistence. Proc Natl Acad Sci U S A 2007; 104:3508.</a></li><li><a class="nounderline abstract_t">Desbonnet C, Tait-Kamradt A, Garcia-Solache M, et al. Involvement of the Eukaryote-Like Kinase-Phosphatase System and a Protein That Interacts with Penicillin-Binding Protein 5 in Emergence of Cephalosporin Resistance in Cephalosporin-Sensitive Class A Penicillin-Binding Protein Mutants in Enterococcus faecium. mBio 2016; 7:e02188.</a></li><li><a class="nounderline abstract_t">Timmler SB, Kellogg SL, Atkinson SN, et al. CroR Regulates Expression of pbp4(5) to Promote Cephalosporin Resistance in Enterococcus faecalis. mBio 2022; 13:e0111922.</a></li><li><a class="nounderline abstract_t">Djorić D, Little JL, Kristich CJ. Multiple Low-Reactivity Class B Penicillin-Binding Proteins Are Required for Cephalosporin Resistance in Enterococci. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Gavaldà J, Len O, Miró JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146:574.</a></li><li><a class="nounderline abstract_t">Tascini C, Doria R, Leonildi A, et al. Efficacy of the combination ampicillin plus ceftriaxone in the treatment of a case of enterococcal endocarditis due to Enterococcus faecalis highly resistant to gentamicin: efficacy of the "ex vivo" synergism method. J Chemother 2004; 16:400.</a></li><li><a class="nounderline abstract_t">Costa Y, Galimand M, Leclercq R, et al. Characterization of the chromosomal aac(6')-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother 1993; 37:1896.</a></li><li><a class="nounderline abstract_t">HAVARD CW, GARROD LP, WATERWORTH PM. Deaf or dead? A case of subacute bacterial endocarditis treated with penicillin and neomycin. Br Med J 1959; 1:688.</a></li><li><a class="nounderline abstract_t">Eliopoulos GM, Farber BF, Murray BE, et al. Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother 1984; 25:398.</a></li><li><a class="nounderline abstract_t">Courvalin P, Carlier C, Collatz E. Plasmid-mediated resistance to aminocyclitol antibiotics in group D streptococci. J Bacteriol 1980; 143:541.</a></li><li><a class="nounderline abstract_t">Mederski-Samoraj BD, Murray BE. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis 1983; 147:751.</a></li><li><a class="nounderline abstract_t">Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000; 31:586.</a></li><li><a class="nounderline abstract_t">Chow JW, Zervos MJ, Lerner SA, et al. A novel gentamicin resistance gene in Enterococcus. Antimicrob Agents Chemother 1997; 41:511.</a></li><li><a class="nounderline abstract_t">Galimand M, Schmitt E, Panvert M, et al. Intrinsic resistance to aminoglycosides in Enterococcus faecium is conferred by the 16S rRNA m5C1404-specific methyltransferase EfmM. RNA 2011; 17:251.</a></li><li><a class="nounderline abstract_t">Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002; 46:1845.</a></li><li><a class="nounderline abstract_t">Sharkey LK, Edwards TA, O'Neill AJ. ABC-F Proteins Mediate Antibiotic Resistance through Ribosomal Protection. mBio 2016; 7:e01975.</a></li><li><a class="nounderline abstract_t">Chenoweth CE, Robinson KA, Schaberg DR. Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis. Antimicrob Agents Chemother 1990; 34:1800.</a></li><li><a class="nounderline abstract_t">Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, et al. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1990; 34:1792.</a></li><li><a class="nounderline abstract_t">Reynolds PE, Arias CA, Courvalin P. Gene vanXYC encodes D,D -dipeptidase (VanX) and D,D-carboxypeptidase (VanY) activities in vancomycin-resistant Enterococcus gallinarum BM4174. Mol Microbiol 1999; 34:341.</a></li><li><a class="nounderline abstract_t">Arias CA, Martín-Martinez M, Blundell TL, et al. Characterization and modelling of VanT: a novel, membrane-bound, serine racemase from vancomycin-resistant Enterococcus gallinarum BM4174. Mol Microbiol 1999; 31:1653.</a></li><li><a class="nounderline abstract_t">Arias CA, Courvalin P, Reynolds PE. vanC cluster of vancomycin-resistant Enterococcus gallinarum BM4174. Antimicrob Agents Chemother 2000; 44:1660.</a></li><li><a class="nounderline abstract_t">Leclercq R, Dutka-Malen S, Duval J, Courvalin P. Vancomycin resistance gene vanC is specific to Enterococcus gallinarum. Antimicrob Agents Chemother 1992; 36:2005.</a></li><li><a class="nounderline abstract_t">Navarro F, Courvalin P. Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens. Antimicrob Agents Chemother 1994; 38:1788.</a></li><li><a class="nounderline abstract_t">Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989; 8:943.</a></li><li><a class="nounderline abstract_t">Fines M, Perichon B, Reynolds P, et al. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother 1999; 43:2161.</a></li><li><a class="nounderline abstract_t">McKessar SJ, Berry AM, Bell JM, et al. Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob Agents Chemother 2000; 44:3224.</a></li><li><a class="nounderline abstract_t">Boyd DA, Willey BM, Fawcett D, et al. Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL. Antimicrob Agents Chemother 2008; 52:2667.</a></li><li><a class="nounderline abstract_t">Lebreton F, Depardieu F, Bourdon N, et al. D-Ala-d-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother 2011; 55:4606.</a></li><li><a class="nounderline abstract_t">Guardabassi L, Agersø Y. Genes homologous to glycopeptide resistance vanA are widespread in soil microbial communities. FEMS Microbiol Lett 2006; 259:221.</a></li><li><a class="nounderline abstract_t">Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993; 37:1563.</a></li><li><a class="nounderline abstract_t">Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995; 33:1434.</a></li><li><a class="nounderline abstract_t">Patel R, Piper K, Cockerill FR 3rd, et al. The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster. Antimicrob Agents Chemother 2000; 44:705.</a></li><li><a class="nounderline abstract_t">Guardabassi L, Christensen H, Hasman H, Dalsgaard A. Members of the genera Paenibacillus and Rhodococcus harbor genes homologous to enterococcal glycopeptide resistance genes vanA and vanB. Antimicrob Agents Chemother 2004; 48:4915.</a></li><li><a class="nounderline abstract_t">Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997; 24:545.</a></li><li><a class="nounderline abstract_t">Reynolds PE, Depardieu F, Dutka-Malen S, et al. Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine. Mol Microbiol 1994; 13:1065.</a></li><li><a class="nounderline abstract_t">Arthur M, Depardieu F, Molinas C, et al. The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin. Gene 1995; 154:87.</a></li><li><a class="nounderline abstract_t">Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 1999; 43:1875.</a></li><li><a class="nounderline abstract_t">Vimberg V, Zieglerová L, Buriánková K, et al. VanZ Reduces the Binding of Lipoglycopeptide Antibiotics to Staphylococcus aureus and Streptococcus pneumoniae Cells. Front Microbiol 2020; 11:566.</a></li><li><a class="nounderline abstract_t">Mevius D, Devriese L, Butaye P, et al. Isolation of glycopeptide resistant Streptococcus gallolyticus strains with vanA, vanB, and both vanA and vanB genotypes from faecal samples of veal calves in The Netherlands. J Antimicrob Chemother 1998; 42:275.</a></li><li><a class="nounderline abstract_t">Stinear TP, Olden DC, Johnson PD, et al. Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet 2001; 357:855.</a></li><li><a class="nounderline abstract_t">Gu L, Cao B, Liu Y, et al. A new Tn1546 type of VanB phenotype-vanA genotype vancomycin-resistant Enterococcus faecium isolates in mainland China. Diagn Microbiol Infect Dis 2009; 63:70.</a></li><li><a class="nounderline abstract_t">Yowler CJ, Blinkhorn RJ, Fratianne RB. Vancomycin-dependent enterococcal strains: case report and review. J Trauma 2000; 48:783.</a></li><li><a class="nounderline abstract_t">Van Bambeke F, Chauvel M, Reynolds PE, et al. Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants. Antimicrob Agents Chemother 1999; 43:41.</a></li><li><a class="nounderline abstract_t">San Millan A, Depardieu F, Godreuil S, Courvalin P. VanB-type Enterococcus faecium clinical isolate successively inducibly resistant to, dependent on, and constitutively resistant to vancomycin. Antimicrob Agents Chemother 2009; 53:1974.</a></li><li><a class="nounderline abstract_t">Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41:2132.</a></li><li><a class="nounderline abstract_t">Leach KL, Swaney SM, Colca JR, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 2007; 26:393.</a></li><li><a class="nounderline abstract_t">Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010.</a></li><li><a class="nounderline abstract_t">Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357:1179.</a></li><li><a class="nounderline abstract_t">Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207.</a></li><li><a class="nounderline abstract_t">Raad II, Hanna HA, Hachem RY, et al. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother 2004; 48:3583.</a></li><li><a class="nounderline abstract_t">Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45:2154.</a></li><li><a class="nounderline abstract_t">Bourgeois-Nicolaos N, Massias L, Couson B, et al. Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo. J Infect Dis 2007; 195:1480.</a></li><li><a class="nounderline abstract_t">Marshall SH, Donskey CJ, Hutton-Thomas R, et al. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002; 46:3334.</a></li><li><a class="nounderline abstract_t">Mendes RE, Deshpande LM, Castanheira M, et al. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008; 52:2244.</a></li><li><a class="nounderline abstract_t">Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007; 64:1506.</a></li><li><a class="nounderline abstract_t">Kehrenberg C, Schwarz S, Jacobsen L, et al. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Mol Microbiol 2005; 57:1064.</a></li><li><a class="nounderline abstract_t">Arias CA, Vallejo M, Reyes J, et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008; 46:892.</a></li><li><a class="nounderline abstract_t">Liu Y, Wang Y, Wu C, et al. First report of the multidrug resistance gene cfr in Enterococcus faecalis of animal origin. Antimicrob Agents Chemother 2012; 56:1650.</a></li><li><a class="nounderline abstract_t">Diaz L, Kiratisin P, Mendes RE, et al. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012; 56:3917.</a></li><li><a class="nounderline abstract_t">Wang Y, Lv Y, Cai J, et al. A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother 2015; 70:2182.</a></li><li><a class="nounderline abstract_t">Cavaco LM, Bernal JF, Zankari E, et al. Detection of linezolid resistance due to the optrA gene in Enterococcus faecalis from poultry meat from the American continent (Colombia). J Antimicrob Chemother 2017; 72:678.</a></li><li><a class="nounderline abstract_t">Pogue JM, Paterson DL, Pasculle AW, Potoski BA. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2007; 28:1382.</a></li><li><a class="nounderline abstract_t">Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346:867.</a></li><li><a class="nounderline abstract_t">Dobbs TE, Patel M, Waites KB, et al. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006; 44:3368.</a></li><li><a class="nounderline abstract_t">Rahim S, Pillai SK, Gold HS, et al. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003; 36:E146.</a></li><li><a class="nounderline abstract_t">Kaatz GW, Lundstrom TS, Seo SM. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 2006; 28:280.</a></li><li><a class="nounderline abstract_t">Pogliano J, Pogliano N, Silverman JA. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol 2012; 194:4494.</a></li><li><a class="nounderline abstract_t">Grein F, Müller A, Scherer KM, et al. Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids. Nat Commun 2020; 11:1455.</a></li><li><a class="nounderline abstract_t">Müller A, Wenzel M, Strahl H, et al. Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains. Proc Natl Acad Sci U S A 2016; 113:E7077.</a></li><li><a class="nounderline abstract_t">Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673.</a></li><li><a class="nounderline abstract_t">Poutsiaka DD, Skiffington S, Miller KB, et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54:567.</a></li><li><a class="nounderline abstract_t">Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56:838.</a></li><li><a class="nounderline abstract_t">Chavada R, Ghosh N, Sandaradura I, et al. Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Britt NS, Potter EM, Patel N, Steed ME. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. Clin Infect Dis 2015; 61:871.</a></li><li><a class="nounderline abstract_t">Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005; 41:565.</a></li><li><a class="nounderline abstract_t">Lewis JS 2nd, Owens A, Cadena J, et al. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005; 49:1664.</a></li><li><a class="nounderline abstract_t">Kamboj M, Cohen N, Gilhuley K, et al. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 2011; 32:391.</a></li><li><a class="nounderline abstract_t">Kelesidis T, Humphries R, Uslan DZ, Pegues D. De novo daptomycin-nonsusceptible enterococcal infections. Emerg Infect Dis 2012; 18:674.</a></li><li><a class="nounderline abstract_t">Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365:892.</a></li><li><a class="nounderline abstract_t">Tran TT, Panesso D, Gao H, et al. Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 2013; 57:261.</a></li><li><a class="nounderline abstract_t">Tran TT, Munita JM, Arias CA. Mechanisms of drug resistance: daptomycin resistance. Ann N Y Acad Sci 2015; 1354:32.</a></li><li><a class="nounderline abstract_t">Tran TT, Panesso D, Mishra NN, et al. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. MBio 2013; 4.</a></li><li><a class="nounderline abstract_t">Khan A, Davlieva M, Panesso D, et al. Antimicrobial sensing coupled with cell membrane remodeling mediates antibiotic resistance and virulence in Enterococcus faecalis. Proc Natl Acad Sci U S A 2019; 116:26925.</a></li><li><a class="nounderline abstract_t">Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45:1343.</a></li><li><a class="nounderline abstract_t">Sakoulas G, Nonejuie P, Nizet V, et al. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother 2013; 57:4042.</a></li><li><a class="nounderline abstract_t">Miller WR, Murray BE, Rice LB, Arias CA. Resistance in Vancomycin-Resistant Enterococci. Infect Dis Clin North Am 2020; 34:751.</a></li><li><a class="nounderline abstract_t">Fiedler S, Bender JK, Klare I, et al. Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M). J Antimicrob Chemother 2016; 71:871.</a></li><li><a class="nounderline abstract_t">Scott LJ. Eravacycline: A Review in Complicated Intra-Abdominal Infections. Drugs 2019; 79:315.</a></li><li><a class="nounderline abstract_t">Barber KE, Bell AM, Wingler MJB, et al. Omadacycline Enters the Ring: A New Antimicrobial Contender. Pharmacotherapy 2018; 38:1194.</a></li><li><a class="nounderline abstract_t">Beabout K, Hammerstrom TG, Perez AM, et al. The ribosomal S10 protein is a general target for decreased tigecycline susceptibility. Antimicrob Agents Chemother 2015; 59:5561.</a></li><li class="breakAll">Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 33rd edition. Clinical Laboratory Standards Institute; Wayne, PA 2023.</li><li><a class="nounderline abstract_t">Coque TM, Murray BE. Identification of Enterococcus faecalis strains by DNA hybridization and pulsed-field gel electrophoresis. J Clin Microbiol 1995; 33:3368.</a></li><li><a class="nounderline abstract_t">Contreras GA, DiazGranados CA, Cortes L, et al. Nosocomial outbreak of Enteroccocus gallinarum: untaming of rare species of enterococci. J Hosp Infect 2008; 70:346.</a></li><li><a class="nounderline abstract_t">Dutka-Malen S, Blaimont B, Wauters G, Courvalin P. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother 1994; 38:1675.</a></li><li><a class="nounderline abstract_t">Johnson AP, Mushtaq S, Warner M, Livermore DM. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar. J Antimicrob Chemother 2004; 53:860.</a></li><li><a class="nounderline abstract_t">Campeau SA, Schuetz AN, Kohner P, et al. Variability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests. Antimicrob Agents Chemother 2018; 62.</a></li></ol></div><div id="topicVersionRevision">Topic 470 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13182750" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1590676" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7860595" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pheromone-inducible conjugation in Enterococcus faecalis: interbacterial and host-parasite chemical communication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404568" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The life and times of the Enterococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3022640" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Conjugative transposons and the dissemination of antibiotic resistance in streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2159259" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Characterization of the Tet M determinants in urogenital and respiratory bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566881" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mechanism of chromosomal transfer of Enterococcus faecalis pathogenicity island, capsule, antimicrobial resistance, and other traits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1489177" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Beta-lactamase-producing enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22075588" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Polyclonal diffusion of beta-lactamase-producing Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22075588" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Polyclonal diffusion of beta-lactamase-producing Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1803989" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9158761" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intrinsic penicillin resistance in enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576454" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Analysis of PBP5 of early U.S. isolates of Enterococcus faecium: sequence variation alone does not explain increasing ampicillin resistance over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15273117" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of specific pbp5 mutations on expression of beta-lactam resistance in Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10748168" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077139" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Balance between two transpeptidation mechanisms determines the expression of beta-lactam resistance in Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25445645" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Penicillin-resistant, ampicillin-susceptible Enterococcus faecalis of hospital origin: pbp4 gene polymorphism and genetic diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903013" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evaluation of polymorphisms in pbp4 gene and genetic diversity in penicillin-resistant, ampicillin-susceptible Enterococcus faecalis from hospitals in different states in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15980374" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32209565" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outcomes of Patients with Bloodstream Infections Caused by Ampicillin-Susceptible but Penicillin-Resistant Enterococcus faecalis: Caution in Interpreting the Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010856" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prospective Observational Study of the Clinical Prognoses of Patients with Bloodstream Infections Caused by Ampicillin-Susceptible but Penicillin-Resistant Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29615500" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Structural and Regulatory Changes in PBP4 Trigger Decreasedβ-Lactam Susceptibility in Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17360674" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A eukaryotic-type Ser/Thr kinase in Enterococcus faecalis mediates antimicrobial resistance and intestinal persistence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27048803" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Involvement of the Eukaryote-Like Kinase-Phosphatase System and a Protein That Interacts with Penicillin-Binding Protein 5 in Emergence of Cephalosporin Resistance in Cephalosporin-Sensitive Class A Penicillin-Binding Protein Mutants in Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35913163" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : CroR Regulates Expression of pbp4(5) to Promote Cephalosporin Resistance in Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32041714" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Multiple Low-Reactivity Class B Penicillin-Binding Proteins Are Required for Cephalosporin Resistance in Enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438316" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332717" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of the combination ampicillin plus ceftriaxone in the treatment of a case of enterococcal endocarditis due to Enterococcus faecalis highly resistant to gentamicin: efficacy of the "ex vivo" synergism method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239603" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characterization of the chromosomal aac(6')-Ii gene specific for Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13629091" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Deaf or dead? A case of subacute bacterial endocarditis treated with penicillin and neomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6326668" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ribosomal resistance of clinical enterococcal to streptomycin isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6259117" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Plasmid-mediated resistance to aminocyclitol antibiotics in group D streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6404994" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-level resistance to gentamicin in clinical isolates of enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987725" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Aminoglycoside resistance in enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055984" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A novel gentamicin resistance gene in Enterococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21159796" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intrinsic resistance to aminoglycosides in Enterococcus faecium is conferred by the 16S rRNA m5C1404-specific methyltransferase EfmM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12019099" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27006457" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : ABC-F Proteins Mediate Antibiotic Resistance through Ribosomal Protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2126692" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2126691" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10564477" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Gene vanXYC encodes D,D -dipeptidase (VanX) and D,D-carboxypeptidase (VanY) activities in vancomycin-resistant Enterococcus gallinarum BM4174.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209740" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Characterization and modelling of VanT: a novel, membrane-bound, serine racemase from vancomycin-resistant Enterococcus gallinarum BM4174.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817725" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : vanC cluster of vancomycin-resistant Enterococcus gallinarum BM4174.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416893" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Vancomycin resistance gene vanC is specific to Enterococcus gallinarum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986009" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2532132" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Structure, biochemistry and mechanism of action of glycopeptide antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471558" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11036060" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458129" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21807981" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : D-Ala-d-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16734783" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Genes homologous to glycopeptide resistance vanA are widespread in soil microbial communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215264" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genetics and mechanisms of glycopeptide resistance in enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7615777" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10681342" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561881" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Members of the genera Paenibacillus and Rhodococcus harbor genes homologous to enterococcal glycopeptide resistance genes vanA and vanB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145724" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Resistance to glycopeptides in enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854121" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7867956" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10428906" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32318043" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : VanZ Reduces the Binding of Lipoglycopeptide Antibiotics to Staphylococcus aureus and Streptococcus pneumoniae Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738855" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Isolation of glycopeptide resistant Streptococcus gallolyticus strains with vanA, vanB, and both vanA and vanB genotypes from faecal samples of veal calves in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11265957" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Enterococcal vanB resistance locus in anaerobic bacteria in human faeces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19073301" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A new Tn1546 type of VanB phenotype-vanA genotype vancomycin-resistant Enterococcus faecium isolates in mainland China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10780621" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Vancomycin-dependent enterococcal strains: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869563" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19273676" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : VanB-type Enterococcus faecium clinical isolate successively inducibly resistant to, dependent on, and constitutively resistant to vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333037" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17499045" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472854" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Antimicrobial resistance to linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11323048" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11476839" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Linezolid resistance in a clinical isolate of Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328133" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11408243" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17436228" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12234875" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391032" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555436" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16091044" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18174304" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22203597" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : First report of the multidrug resistance gene cfr in Enterococcus faecalis of animal origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491691" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25977397" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27999039" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Detection of linezolid resistance due to the optrA gene in Enterococcus faecalis from poultry meat from the American continent (Colombia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17994519" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11893808" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16954275" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766857" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16963232" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Mechanisms of daptomycin resistance in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22661688" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32193379" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27791134" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15227611" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17188750" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123698" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28242672" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063715" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16028170" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793168" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460492" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Emergence of daptomycin-resistant VRE: experience of a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22469288" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : De novo daptomycin-nonsusceptible enterococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21899450" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Genetic basis for in vivo daptomycin resistance in enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23114757" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26495887" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Mechanisms of drug resistance: daptomycin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23882013" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31818937" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Antimicrobial sensing coupled with cell membrane remodeling mediates antibiotic resistance and virulence in Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968832" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23689728" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33131572" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Resistance in Vancomycin-Resistant Enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26682961" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30783960" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Eravacycline: A Review in Complicated Intra-Abdominal Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30290000" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Omadacycline Enters the Ring: A New Antimicrobial Contender.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124155" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The ribosomal S10 protein is a general target for decreased tigecycline susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124155" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The ribosomal S10 protein is a general target for decreased tigecycline susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8586745" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Identification of Enterococcus faecalis strains by DNA hybridization and pulsed-field gel electrophoresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799242" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Nosocomial outbreak of Enteroccocus gallinarum: untaming of rare species of enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979308" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15056637" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941639" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Variability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
